Crossmark

Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future—An Industry View

Crossref DOI link: https://doi.org/10.1007/s43441-023-00536-y

Published Online: 2023-06-02

Published Print: 2023-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Geraci, Gaia https://orcid.org/0000-0003-0498-1873
Bernat, Janis

Rodier, Céline

Acha, Virginia

Acquah, Jaqueline

Beakes-Read, Ginny
Funding

Funding for this research was provided by:

IFPMA
License Information

Text and Data Mining valid from 2023-06-02

Version of Record valid from 2023-06-02
More Information

Article History

Received: 20 October 2022

Accepted: 28 April 2023

First Online: 2 June 2023

Declarations

:

: GG and CR declare that they have no conflict of interest. JB declares that she has no conflict of interest (besides being employed by the non-profit organization IFPMA). VA, JA and GBR are employed by pharmaceutical companies and are members of IFPMA, but declare that they have no conflict of interest directly related to the article’s content.

Document is current

Any future updates will be listed below